Denali Therapeutics

Youtube Subscribe

Open: 21.87 Close: 20.93 Change: -0.94

You don't have time to read all about Denali Therapeutics. An AI summarizes all the information for you.

Are looking for the most relevant information about Denali Therapeutics? Investor spend a lot of time searching for information to make investment decisions in Denali Therapeutics. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Denali Therapeutics are: Denali, Therapeutics, share, patent, Inc, price, Buy, and the most common words in the summary are: therapeutic, denali, job, company, inc, share, stock, . One of the sentences in the summary was: Oppenheimer maintains a Buy rating on Denali.. Other searches related to …

Concept Map

Semantic Network

Stock Summary

Denali Therapeutics Inc. discovers and develops therapeutic candidates for neurodegenerative and lysosomal diseases. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate product candidate..

Today's Summary

Denali Therapeutics Inc. (NASDAQ:dnli) shares sold by Trexquant investment lp - defense world.org - Defense World Staff on Mar 7th, 2024. Goldman Sachs Group decreased their price objective on shares of Denali. Oppenheimer maintains a Buy rating on Denali.

Today's News

GlobalDatas report on Denali Therapeutics gives a 360-degree view of the company including its patenting strategy. Cancer treatment biomarkers was a key innovation area identified from patents. Denalis grant share as of January 2024 was 16%. Denali Therapeutics Inc. (NASDAQ:DNLI) Reports First Quarter 2023 Financial Results and Business Highlights. Denali Therapeutics Inc. (NASDAQ:dnli) shares sold by Trexquant investment lp - defense world.org - Defense World Staff on Mar 7th, 2024. The Goldman Sachs Group decreased their price objective on shares of Denali. Oppenheimer maintains a Buy rating on Denali Therapeutics ( DNLI – Research Report ) with a price target of $60.00. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Denali.

Stock Profile

"Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative and lysosomal diseases in the United States and internationally. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease; TAK-594/DNL593, which is in Phase I/II clinical trials for the treatment of frontotemporal dementia-granulin; TAK-920/DNL919, which is in Phase I clinical trials for the treatment of Alzheimer's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); SAR443820/DNL788, which is in phase II clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreements with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, Genzyme Corporation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California."

Keywords

The game is changing. There is a new strategy to evaluate Denali Therapeutics fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Denali Therapeutics are: Denali, Therapeutics, share, patent, Inc, price, Buy, and the most common words in the summary are: therapeutic, denali, job, company, inc, share, stock, . One of the sentences in the summary was: Oppenheimer maintains a Buy rating on Denali.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #denali #job #company #inc #share #stock.

Read more →

Youtube Subscribe

---